SNDX Q1 2020 Earnings — Syndax Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

SNDXSyndax Pharmaceuticals, Inc.

$2B

Q1 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$379,000+0.0% YoY

Gross Profit

$379,000100.0% margin

Operating Income

-$15M-3984.2% margin

Net Income

-$15M-4020.1% margin

EPS (Diluted)

$-0.44

QoQ Revenue Growth

-0.3%

Cash Flow

Operating Cash Flow

-$16M

Free Cash Flow

-$16M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$105M

Total Liabilities

$52M

Stockholders' Equity

$54M

Cash & Equivalents

$45M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$379,000	$379,000	+0.0%
Gross Profit	$379,000	$379,000	+0.0%
Operating Income	-$15M	-$15M	-2.0%
Net Income	-$15M	-$14M	-6.5%